Pressure Bio, Target Discovery Expand Deal for PCT Platform into Clinical Dx Testing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences and Target Discovery today announced they have expanded a technology license and supply agreement.

Under the expansion, Target Discovery will be able to use Pressure Bio's Pressure Cycling Technology platform for a planned entry into the clinical diagnostics testing space, they said, adding that the planned diagnostic services target critical unmet needs in treatment selection guidance for ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.